Co-founders of China's 111 Inc. Propose Buyout to Go Private

Key Facts

1111 Inc.'s board received a non-binding buyout proposal from its co-founders at $4.52 per American Depositary Share.

2The company reported Q2 2026 results showing a widened net loss alongside a strategic shift to an asset-light business model.

Amid structural shifts in China's digital healthcare sector, 111 Inc. announced that its board of directors has received a non-binding buyout proposal from its co-founders to take the company private. The proposal offers a purchase price of $4.52 per American Depositary Share (ADS). This move coincides with the release of the company's Q2 2026 financial results, which highlighted a widening net loss as the firm continues its strategic transition toward an asset-light business model.

According to reports, the co-founders intend to steer the company through a transition focused on integrating artificial intelligence into its core operations. Despite the financial pressure of increased losses, the strategic shift aims to leverage the asset-light model to optimize operational efficiency. As the proposal is currently non-binding, it remains subject to negotiation and formal board approval before any definitive agreement is reached.

Based on available market data, current price levels for the instrument are unavailable; however, the $4.52 buyout offer is expected to provide a qualitative floor for the stock's valuation. Investors should also consider the broader regional context, as recent data from China on September 14, 2026, showed new loans falling to 60 billion against a 400 billion forecast, reflecting a cautious credit environment that may impact the financing landscape for such corporate transactions.